Shanghai Pharmaceuticals has priced its proposed initial public offering in Hong Kong, which will top $2.13 billion, according to Pharma Times.

Shanghai Pharmaceuticals is China's second-largest distributor of pharmaceutical products and the country's third-largest drug manufacturer.